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Abstract Heterozygous carriers of ATM mutations are at
increased risk of breast cancer. In this case-control study,
we evaluated the signiﬁcance of germline ATM missense
variants to the risk of contralateral breast cancer (CBC).
We have determined the spectrum and frequency of ATM
missense variants in 443 breast cancer patients diagnosed
before age 50, including 247 patients who subsequently
developed CBC. Twenty-one per cent of the women with
unilateral breast cancer and 17% of the women with CBC
had at least one ATM germline missense variant, indicating
no signiﬁcant difference in variant frequency between
these two groups. We have found that carriers of an ATM
missense mutation, who were treated with radiotherapy for
the ﬁrst breast tumour, developed their second tumour on
average in a 92-month interval compared to a 136-month
mean interval for those CBC patients who neither received
RT nor carried a germline variant, (p = 0.029). Our results
indicate that the presence of ATM variants does not have a
major impact on the overall risk of CBC. However, the
combination of RT and (certain) ATM missense variants
seems to accelerate tumour development.
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Introduction
Homozygous or compound heterozygous germline
mutations in the ATM gene cause the autosomal recessive
disorder ataxia-telangiectasia (A-T). This progressive
neurological childhood disease is characterized by
cerebellar degeneration, immunological defects, extreme
sensitivity for ionising radiation and increased risk for
cancers, particularly lymphomas [1]. ATM mutations
identiﬁed in A-T families can be classiﬁed in three cate-
gories; truncating mutations, mutations that lead to some
expression of mutant protein that lacks kinase activity and
missense mutations with reduced kinase activity (http://
chromium.liacs.nk/lovd/).
Heterozygous pathogenic ATM mutation carriers,
~0.5–1% of the general population, do not display the
symptoms observed in A-T patients. Several epidemio-
logical studies have consistently shown elevated rates of
breast cancer among female blood relatives of patients with
A-T [2, 3]. Thompson et al. have shown that the overall
relative risk in carriers was 2.23 [95% conﬁdence interval
(CI) 1.16–4.28] compared to the general population and
4.95 (95% CI 1.9–12.9) in those younger that age 50. A
large review showed that ATM mutations are more frequent
in breast cancer patients selected on the basis of a family
history of breast cancer than in unselected patients [4].
Besides pathogenic ATM mutations, a large number of
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variants) have been described, which were found in cancer
patients as well as in the general population. It has been
hypothesized that the cancer risk among ATM heterozyg-
otes might be related to mutation type, suggesting that
particularly missense mutations are associated with an
increased risk [5, 6]. However, two recent studies by
Thompson et al. and Renwick et al. showed that patho-
genic ATM mutations that cause A-T are breast cancer
susceptibility alleles [2, 7]. This argues against the
hypothesis that missense rather that truncating are associ-
ated with breast cancer.
Women with breast cancer have in general a three to
fourfold increased risk of developing a new primary cancer
in the opposite breast [8]. The contralateral breast cancer
(CBC) risk might be explained by the same genetic and
hormonal factors that caused the ﬁrst breast cancer.
Treatment related factors, e.g. radiotherapy for primary
breast cancer, may also contribute to the development of
cancer in the contralateral breast [9] (our own data,
manuscript under review).
To evaluate whether germline ATM missense variants
are signiﬁcantly associated with CBC risk (results regard-
ing ATM truncating mutations are reported elsewhere) and
whether treatment modiﬁes this risk, we conducted a
case-control study in which we assessed the ATM missense
mutation spectrum and frequency in women who devel-
oped their ﬁrst breast cancer before age 50, with and
without a second primary breast cancer.
Methods
Patients
The consecutive breast cancer patients included in this
study were all selected from the hospital tumour regis-
tries of The Netherlands Cancer Institute, Amsterdam
(NKI-AVL) or The Dr. Daniel den Hoed Cancer Center/
Erasmus Medical Center, Rotterdam (DDHK). Of all
patients that were invited to participate we achieved an
80% response rate. The breast cancer patients were
included if their (ﬁrst) breast cancer was diagnosed
before age 50 (n = 443). For CBC we required an
interval of at least 1 year (n = 247). The unilateral breast
cancer patients (UBC) patients all had to be disease-free
(of a second breast cancer) for at least 5 years. The ﬁrst
57 CBC patients were individually age-matched (1:3) to
UBC controls. All patients had invasive breast carcinoma
and were treated with surgery. Of the CBC patients 169
did and 78 did not receive radiotherapy treatment for
their primary breast tumour. Average age at diagnosis
for the ﬁrst breast cancer in the RT group was
41.2/41.3 years (mean/median) and the non-exposed
group 42.0/43.2 years (mean/median). Detailed treatment
data, disease and patient characteristics were obtained
from medical records and risk factor questionnaires (data
not shown) [10, 11]. Patients were asked to donate a
20 ml blood sample or permission for use of parafﬁn-
embedded tissue blocks and patients gave their written
informed consent for mutation analysis. This study
received approval of the Medical Ethical Committees of
NKI-AVL and DDHK.
Genomic DNA isolation
Genomic DNA was either isolated from peripheral blood
lymphocytes with DNAzol (Invitrogen, Breda, The
Netherlands) methods according to the manufacturer’s
instructions, or from three 10-lm parafﬁn embedded
normal tissue slides according to standard protocols [12].
For histopathological examination we used a hematoxylin-
eosin stained slide.
Mutation analysis
The complete ATM Open Reading Frame (ORF) was
analysed, each exon (exon 4-65) and all intron-exon
boundaries were screened for germline mutations using
Denaturing Gradient Gel Electrophoresis (DGGE) identi-
fying ~90% of all ATM mutations and polymorphisms
(details from the author upon request). All aberrations were
conﬁrmed with genomic sequence analysis, performed
using the ABI PRISM BigDyeTerminator Cycle Sequenc-
ing Ready Reaction Kit Version 3.1 (Applied Biosystems,
Nieuwerkerk a/d yssel, The Netherlands). Sequencing
products were analysed with the ABI PRISM 3700 DNA
Analyzer and corresponding software.
Statistical analysis
Statistical analyses were performed using standard
methods for analysis of case-control studies [13]. We
compared the mutation frequency between UBC and CBC
and between CBC cases previously treated with RT and
cases not-treated with RT. Odds ratios (ORs) and 95% CI
were calculated to evaluate the association between
mutation carriers status and breast cancer risk. We have
used the Mann–Whitney test to determine whether the
difference between the intervals between the two breast
cancers of the CBC patients was signiﬁcant. All analyses
were performed using SPSS 12.0 (SPSS Inc., Chicago,
IL, USA).
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ATM germline mutations
In the present study, we have used the DGGE method to
screen the complete ATM ORF to obtain insight in the ATM
missense mutation spectrum in (contralateral) breast cancer
patients. With DGGE we were able to conﬁrm all the
previously identiﬁed truncating mutations. A subset of the
CBC patients described in this study had been screened in
the past for ATM truncating mutations with the Protein
Truncating Test, revealing seven ATM truncating mutations
(including a non-sense mutation and small insertions and
deletions; generating stop codons within a previously
functional protein coding sequence causing premature
termination of translation of the protein) [10]. Among all
443-breast cancer patients that were tested in this study
with DGGE we detected a large number of ATM silent
mutations (presumed neutral polymorphisms, data not
shown and excluded from all analyses) and missense
mutations (causing an amino acid substitution in the coded
protein, most common ones; i.e. D1853N, not included in
further analysis).
ATM missense mutation spectrum
In our study cohort we have detected 35 distinct ATM
missense variants and 6 distinct truncating mutations.
Several of the detected missense variants have been
reported in the ATM database as being detected in A-T
patients/or as polymorphisms (Table 1). None of the
missense variants identiﬁed in this study are known as
pathogenic A-T causing missense mutations. Seventeen of
the missense variants have not been reported previously.
Eleven missense variants were exclusively found in the
CBC group and 10 exclusively in the UBC group. Whether
this distinction in the spectrum indicates an association
between particular variants and bilateral breast cancer risk
cannot be concluded from the small numbers obtained in
this study population. The ATM protein has several
functional domains and the identiﬁed missense variants are
located throughout the ORF. Potential functional implica-
tions of the newly identiﬁed unclassiﬁed variants remain to
be established.
Despite the fact that ATM plays a role in breast cancer
risk, the role of most distinct ATM missense variants
remains unclear. Some studies tried to predict the relevance
of each particular mutation on basis of co-segregation with
breast cancer in families, the location in a functional
domain or interference with the splicing machinery. Only a
few studies present functional analysis that are necessary to
assess the biological impact of unidentiﬁed variants found
frequently in ATM [18–20].
ATM missense mutations and contralateral breast
cancer
Twenty-one per cent of the patients carried at least one
ATM germline variant (missense and truncating; Table 2).
Among the patients with CBC (n = 247) we identiﬁed in
total 55 ATM variants in 45 individuals (18%); 51 missense
variants and 4 truncating mutations (Table 2). Eight CBC
patients had multiple ATM missense variants and 2 patients
carried both a missense and a truncating ATM mutation. In
the women with UBC (n = 196) we identiﬁed 52 ATM
variants in 46 individuals (23%); 48 missense and 4
truncating mutations. Three UBC patients carried double
missense and 3 patients both a truncating and a missense
variant. Although it is known from the literature that ATM
missense variants might be involved in breast cancer
pathogenesis, the identiﬁed 17% missense variant carriers
among the CBC patients compared to the 21% missense
variants among the UBC patients indicate that there is not a
signiﬁcantly increased risk for bilateral breast cancer
among ATM missense variant carriers, OR 0.77 (95% CI
0.48–1.24).
Association with radiation treatment
Women at high risk for developing breast cancer may
respond differently to radiation exposures associated with
screening and treatment, than the general population.
Candidate-genes like ATM are implicated in maintenance
of genome integrity. Their involvements in breast cancer
susceptibility as well as their role in DNA-damage repair
signalling make them excellent candidates for a role in
radiation-induced breast cancer [21]. Recently, we showed
that women with a pathogenic germline mutation in a DNA
repair pathway gene (e.g. BRCA1, BRCA2, CHEK2 and
ATM) have an over 2-fold increased risk of developing
radiation-associated breast cancer (manuscript under
review). Therefore, we now investigated whether exposure
to ionising radiation had a greater biological impact on
certain ATM genotypes than on others.
We did not detect a signiﬁcantly increased risk of
developing radiation-associated CBC among missense
mutation carriers. Among those 169 CBC patients who had
developed a second primary breast tumour following
radiotherapy for their ﬁrst breast tumour we identiﬁed
19.5% ATM missense variants carriers compared to 13%
among those CBC patients who did not receive RT, the OR
from this case-only analysis is 1.65 [95% CI (0.77–3.55)
p = 0.2]. Furthermore, we have observed that 21% of the
UBC patients, who received RT but did not develop a CBC
carried an ATM missense variant, compared to 19.5% of
the CBC patients that received RT for their ﬁrst tumour
[OR 0.86 (95% CI 0.52–1.43)]. These results suggest that
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123Table 1 ATM missense variant and truncating mutation spectrum in contralateral and unilateral breast cancer patients
Missense variants Amino acid change CBC n = 247 UBC n = 190 Database
a or literature
37C>T R13C 1 [10]
146C>G S49C 5 5 database
162T>C Y54H 2 1 [4], [14]
378A>T D126E 1 database
1009C>T R337C 1 Novel
1132A>G S377G 1 Novel
1229T>G V410A 2 1 [4]
1810C>T P604S 1 database
2119T>C S707P 7 8 database
2276G>A S759N Novel
2336T>C M779T 1 Novel
2414G>A R805Q 2 Novel
2572T>C F858L 4 3 database
2650C>T P884S 1
2650C>T P884S 1 Novel
2614C>T P872S [15]
3161C>G P1054R 8 13 database
3925G>A A1309T 1 1 [16]
4138C>T H1380Y 1 database
4258C>T L1420F 5 4 database
4324T>C Y1442H 2 Novel
4362A>C K1454N 1 database
4477C>G L1493V 1 Novel
4664T>A L1555H 1 Novel
4722G>T L1574F 1 Novel
5044G>T D1682Y 1 database
5071A>C S1691R 2 2 database
5557G>A
b D1853N 35 49 database
5558A>T D1853V 3 1 database
5741A>G D1914G Novel
6067G>A G2023R 1 database
6820G>A A2274T 1 database
6919C>T L2307F 1 [14]
7446G>A M2482I 1 Novel
7874A>G D2625G 1 Novel
8659C>G H2887D 1 Novel
Truncating mutations
IVS10-6T>G 419X 1 2 database [10], [17]
1563delAG 521X 1 database
1660delA 554X 1 Novel
IVS14 + 2T>G del 601-633 1 database
2572insT F858X 1 Novel
3115A>T R1039X 1 Novel
a http://chromium.liacs.nk/lovd/
b Not included in frequency analysis
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123RT is not a strong risk factor for the development of CBC
among carriers of those ATM missense variants.
It has however been shown that particular alterations in
the ATM gene are associated with increased radiation
sensitivity [22–24]. Gutierrez-Enriquez et al. showed that
lymfoblastoid cell lines carrying the ATM variant 3161G
(linked to 2572C) was associated with increased in vitro
chromosomal radio-sensitivity, perhaps by interfering with
ATM function in a dominant-negative manner [22]. We
found this particular variant allele (3161G/2572C)
exclusively in our CBC group exposed to radiotherapy
(four times) and not in the non-RT-exposed CBC group.
This ﬁnding supports the hypothesis that particular ATM
variants might play a differential role in radiation response.
Although a subset of the missense variants was only
detected in the RT exposed subpopulation, individual
numbers were probably too small to detect a signiﬁcant
effect of particular mutations associated with treatment.
We observed that CBC patients with an ATM missense
variant had an mean interval between the ﬁrst and second
breast tumour of ~101 months, compared to 122 months
for non-carriers CBC patients (p = 0.085). Interestingly,
the combination of radiation treatment and a missense
variant resulted in an even shorter mean interval of a
92 months in the CBC patients compared to a 136-month
interval for CBC patients who neither received RT nor
carried a germline variant (p = 0.029). These data suggest
that carrier-ship of an ATM missense variant may accel-
erate the development of a second tumour and decreases
the age at onset of the second breast tumour, especially in
case of exposure to RT.
The suggestion of a shorter induction period of
RT-associated breast cancer in patients, who carry an ATM
missense mutation, while the proportion of patients with
missense variants was similar in CBC and UBC cases,
might be attributable to a different spectrum of mutations
in those patients who developed CBC. A big challenge in
such a study remains to assess which particular missense
mutations have an impact on ATM function. Large
association studies, as performed by the Breast Cancer
Association Consortium (coordinated by Doug Easton and
Paul Pharoah, Cambridge), and functional studies are
clearly necessary to determine the importance of particular
variants and their contribution to the breast cancer risk.
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